Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress
Recommended Citation
Gupta K, Hinkamp C, Andrews T, Meloche C, Minhas AMK, Slipczuk L, Vaughan E, Habib FZ, Sheikh S, Kalra D, and Virani SS. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep 2023; 25(12):965-978.
Document Type
Article
Publication Date
12-1-2023
Publication Title
Current atherosclerosis reports
Abstract
PURPOSE OF REVIEW: To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 European Society of Cardiology (ESC) congress.
RECENT FINDINGS: The NATURE-PARADOX was a naturally randomized trial that used genetic data from the UK Biobank registry to create "cumulative exposure to low-density lipoprotein-cholesterol (LDL-C)" biomarker and evaluate its association with major CV events regardless of plasma LDL-C levels or age. Safety and efficacy data of inclisiran, a PCSK9-interfering mRNA (PCSK9i) administered subcutaneously twice annually, were presented. Data on two new PCSK9is were presented, recaticimab, an oral drug, and lerodalcibep, a subcutaneous drug with a slightly different architecture than currently available PSCK9is. A phase 1 trial on muvalaplin, an oral lipoprotein (a) inhibitor, was presented. An atherosclerotic CV disease (ASCVD) risk prediction algorithm for the Asian population using SCORE2 data was presented. Long-term follow-up of patients enrolled in the CLEAR outcomes trial showed sustained and more significant ASCVD risk reduction with bempedoic acid in high-risk patients. The late-breaking clinical science at the 2023 congress of the ESC extends the known safety and efficacy data of a PCSK9i with the introduction of new drugs in this class. Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine.
Medical Subject Headings
Humans; Proprotein Convertase 9; Cholesterol, LDL; Cardiovascular Diseases; Cardiology; Anticholesteremic Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors
PubMed ID
37975955
ePublication
ePub ahead of print
Volume
25
Issue
12
First Page
965
Last Page
978
